|
1
|
Dalton E and Thompson J: AB054. Overview
of multi-gene panels for hereditary cancer. Ann Transl Med.
3:AB0542015.
|
|
2
|
Lincoln SE, Kobayashi Y, Anderson MJ, Yang
S, Desmond AJ, Mills MA, Nilsen GB, Jacobs KB, Monzon FA, Kurian
AW, et al: A systematic comparison of traditional and multigene
panel testing for hereditary breast and ovarian cancer genes in
more than 1000 patients. J Mol Diagn. 17:533–544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo XE, Ngo B, Modrek AS and Lee WH:
Targeting tumor suppressor networks for cancer therapeutics. Curr
Drug Targets. 15:2–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Q, Madden NE, Wong AST, Chow BKC and
Lee LTO: The role of endocrine G protein-coupled receptors in
ovarian cancer progression. Front Endocrinol (Lausanne).
8:662017.PubMed/NCBI
|
|
6
|
Shuch B, Hahn AW and Agarwal N: Current
treatment landscape of advanced papillary renal cancer. J Clin
Oncol. 35:2981–2983. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ross H, Martignoni G and Argani P: Renal
cell carcinoma with clear cell and papillary features. Arch Pathol
Lab Med. 136:391–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman AA, Letai A, Fisher DE and
Flaherty KT: Precision medicine for cancer with next-generation
functional diagnostics. Nat Rev Cancer. 15:747–756. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lodish H, Berk A, Zipursky SL, Matsudaira
P, Baltimore D and Darnell J: The Role of topoisomerases in DNA
replication. Molecular Cell Biology. 4th edition. W.H. Freeman; New
York, NY: 2000
|
|
10
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W:
Topoisomerase IIα in chromosome instability and personalized cancer
therapy. Oncogene. 34:4019–4031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Resende MF, Vieira S, Chinen LT,
Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I,
Pagotty S, Pellionisz PA, et al: Prognostication of prostate cancer
based on TOP2A protein and gene assessment: TOP2A in prostate
cancer. J Transl Med. 11:362013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fountzilas G, Valavanis C, Kotoula V,
Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R,
Wirtz RM, Bobos M, et al: HER2 and TOP2A in high-risk early breast
cancer patients treated with adjuvant epirubicin-based dose-dense
sequential chemotherapy. J Transl Med. 10:102012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito F, Furukawa N and Nakai T: Evaluation
of top2a as a predictive marker for endometrial cancer with
taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer.
26:325–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Erriquez J, Becco P, Olivero M, Ponzone R,
Maggiorotto F, Ferrero A, Scalzo MS, Canuto EM, Sapino A, Verdun di
Cantogno L, et al: TOP2A gene copy gain predicts response of
epithelial ovarian cancers to pegylated liposomal doxorubicin:
TOP2A as marker of response to PLD in ovarian cancer. Gynecol
Oncol. 138:627–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tarpgaard LS, Qvortrup C, Nygård SB,
Nielsen SL, Andersen DR, Jensen NF, Stenvang J, Detlefsen S,
Brünner N and Pfeiffer P: A phase II study of epirubicin in
oxaliplatin-resistant patients with metastatic colorectal cancer
and TOP2A gene amplification. BMC Cancer. 16:912016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F
and Fan Y: TOP2A amplification in breast cancer is a predictive
marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Breast Cancer Res Treat. 135:531–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheburkin IuV, Kniazeva TG, Peter S,
Kniazev IuP, Karelin MI, Shkol'nik MI, Evtushenko VI, Hanson KP,
Ullrich A and Kniazev PG: Molecular portrait of human kidney
carcinomas: The gene expression profiling of protein-tyrosine
kinases and tyrosine phosphatases which controlled regulatory
signals in the cells. Mol Biol (Mosk). 36:480–490. 2002.(In
Russian). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen D, Maruschke M, Hakenberg O,
Zimmermann W, Stief CG and Buchner A: TOP2A, HELLS, ATAD2 and TET3
are novel prognostic markers in renal cell carcinoma. Urology.
102:265 e1–265 e7. 2017. View Article : Google Scholar
|
|
19
|
Grossman RL, Heath AP, Ferretti V, Varmus
HE, Lowy DR, Kibbe WA and Staudt LM: Toward a shared vision for
cancer genomic data. N Engl J Med. 375:1109–1112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones J, Otu H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dannull J, Su Z, Rizzieri D, Yang BK,
Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E and Vieweg
J: Enhancement of vaccine-mediated antitumor immunity in cancer
patients after depletion of regulatory T cells. J Clin Invest.
115:3623–3633. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anaya J: OncoLnc: Linking TCGA survival
data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science.
2:e672016. View Article : Google Scholar
|
|
25
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:p112013. View Article : Google Scholar
|
|
26
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cbio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles
S, Tandy S, Pesaran T, Chen E, Gau CL, Palmaer E, Shoaepour K, et
al: Utilization of multigene panels in hereditary cancer
predisposition testing: Analysis of more than 2,000 patients. Genet
Med. 16:830–837. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ronnen EA, Kondagunta GV, Ishill N, Spodek
L, Russo P, Reuter V, Bacik J and Motzer RJ: Treatment outcome for
metastatic papillary renal cell carcinoma patients. Cancer.
107:2617–2621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F
and Fan Y: TOP2A amplification in breast cancer is a predictive
marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Breast Cancer Res Treat. 135:531–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parker AS, Eckel-Passow JE, Serie D,
Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC and Leibovich
BC: Higher expression of topoisomerase II alpha is an independent
marker of increased risk of cancer-specific death in patients with
clear cell renal cell carcinoma. Eur Urol. 66:929–935. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barr FA, Silljé HH and Nigg EA: Polo-like
kinases and the orchestration of cell division. Nat Rev Mol Cell
Biol. 5:429–440. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kufer TA, Silljé HH, Körner R, Gruss OJ,
Meraldi P and Nigg EA: Human TPX2 is required for targeting
Aurora-A kinase to the spindle. J Cell Biol. 158:617–623. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parvin JD, Kais Z, Arora M, Kotian S, Zha
A, Ransburgh D, Bozdag D, Catalyurek U and Huang K: Identification
of a breast cancer associated regulatory network. Proceedings of
the 2009 Ohio Collaborative Conference on Bioinformatics.
Bioinformatics Cleveland, OH: pp. 71–75. 2009, View Article : Google Scholar
|
|
36
|
Taylor SS, Scott MI and Holland AJ: The
spindle checkpoint: A quality control mechanism which ensures
accurate chromosome segregation. Chromosome Res. 12:599–616. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kolodner RD and Marsischky GT: Eukaryotic
DNA mismatch repair. Curr Opin Genet Dev. 9:89–96. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rath O and Kozielski F: Kinesins and
cancer. Nat Rev Cancer. 12:527–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu Y and Feng YM: The role of kinesin
family proteins in tumorigenesis and progression: Potential
biomarkers and molecular targets for cancer therapy. Cancer.
116:5150–5160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hong KU, Kim E, Bae CD and Park J:
TMAP/CKAP2 is essential for proper chromosome segregation. Cell
Cycle. 8:314–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
DeLuca JG, Dong Y, Hergert P, Strauss J,
Hickey JM, Salmon ED and McEwen BF: Hec1 and nuf2 are core
components of the kinetochore outer plate essential for organizing
microtubule attachment sites. Mol Biol Cell. 16:519–531. 2005.
View Article : Google Scholar : PubMed/NCBI
|
